Navigation Links
Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
Date:8/18/2010

ent populations and an independent Data Safety Monitoring Board recommended continuation of QPI-1002 clinical development in both diseases. QPI-1002 was granted Orphan designation by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the prophylaxis of delayed graft function in kidney transplant patients.

About Quark Pharmaceuticals, Inc.Quark Pharmaceuticals, Inc., a world leader in novel RNAi discovery and development, has the largest clinical-stage siRNA pipeline in the industry. The Company's fully integrated drug development platform spans therapeutic target identification to drug development.  Quark's approach to delivery allows targeting of tissues and organs including the eye, kidney, ear, lung, spinal cord and brain.

In addition to QPI-1002, Quark's pipeline includes PF-655, currently in two Phase II clinical trials for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The siRNA therapeutic candidate PF-655 is licensed to Pfizer, who is conducting both trials in collaboration with Quark. PF-655 targets Quark's proprietary gene, RTP801, discovered using its BiFAR™ target discovery platform that identifies clinically relevant critical genes and proteins that reverse the disease phenotype when inhibited. The Company owns a family of patents covering the RTP801 gene, its RNA and protein product sequences, specific antibodies, and gene inhibition across different pathologies. For the structure of these products, Quark has obtained licenses from Silence Therapeutics and from Alnylam Pharmaceuticals.

Quark is currently conducting clinical trials of QPI-1007, its proprietary synthetic siRNA drug candidate for ocular neuroprotection. QPI-1007 utilizes a proprietary structure developed in collaboration with BioSpring GmbH that provides Quark with freedom to operate in the siRNA intellectual property arena and chemical modifications that are designed to pr
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 ... of the "Physician Office Laboratory Markets, 3rd ... This report, Physician Office Laboratory Markets is ... the IVD industry. Physician office laboratories are diverse ... simply perform reimbursable, in-office pregnancy and glucose tests. ...
(Date:9/23/2014)... The Pennsylvania State Police will accept unwanted, expired ... of National Prescription Drug Take-Back Day. The service is ... Day is a national initiative, conducted in partnership with ... the public to dispose of expired, unused or unwanted ... From 10 a.m. to 2 p.m., unwanted ...
(Date:9/23/2014)... , Sept. 23, 2014 Research and ... "Biopharmaceutical and Vaccine Production Markets" report to their ... new therapies and vaccines - including products to treat ... still huge challenges during the final stages of clinical ... and how to risk production capital to upscale while ...
Breaking Medicine Technology:Physician Office Laboratory Markets, 3rd Edition 2Physician Office Laboratory Markets, 3rd Edition 3Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), ... and commercialization of its proprietary stent platform technology, ... summary of  three years collective data will be ... Transcatheter Cardiovascular Therapeutics (TCT) conference. The conference is ...
... Express Scripts, Inc., one of the largest ... Rexam as its 2011 Supplier of the Year. ... This award recognizes suppliers who have a ... continuous improvement in supplier relationship management, quality, service, ...
Cached Medicine Technology:InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 2InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 3InspireMD to Sponsor Satellite Symposium Breakfast Meeting Chaired by Dr. Gregg W. Stone November 9th at TCT 2011 4Rexam Chosen as Express Scripts' Supplier of the Year 2
(Date:9/23/2014)... 24, 2014 Menopause can cause ... roughly half of women, menopause can trigger debilitating ... commonly associated with major depressive disorder. These ... disturbances, memory loss, and fatigue. While hormone ... effects and high cost make them an unsuitable ...
(Date:9/23/2014)... NY (PRWEB) September 23, 2014 The ... moderate rate over the past five years. Growth in ... consciousness has encouraged Canadians to consume more fish and ... encouraged food retailers and food-service establishments to increase their ... industry revenue. Additionally, strong economic growth in much of ...
(Date:9/23/2014)... Mo. Infants, vocalizations throughout the first year ... and cooing to forming syllables and first words. ... amount of vocalizations may differ between hearing and ... that infant vocalizations are primarily motivated by infants, ... with profound hearing loss who received cochlear implants ...
(Date:9/23/2014)... NIH TO CONVENE PATHWAYS TO PREVENTION WORKSHOP: ROLE OF ... WHAT: , The National Institutes of Health is ... available scientific evidence on the long-term effectiveness and potential ... be among the nation,s top experts in the field ... as well as key NIH scientists who focus on ...
(Date:9/23/2014)... Diego, CA (PRWEB) September 23, 2014 ... daily regarding all the latest information from the FDA ... on September 5, that its Private Label Jalapeno Bagels ... and small stones. Publix Jalapeno Bagels were ... the bakery department. , Taking into consideration the ...
Breaking Medicine News(10 mins):Health News:Pristiq Discounts Now Available from MedicationDiscountCard.com To Help Ease Menopause Symptoms 2Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Fish and Seafood Wholesaling in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... American Cancer Society, the largest non-government, not-for-profit funding source ... 152 new national research and training grants totaling $50,717,000 ... The grants, primarily to early career researchers, cover a ... from whether cadmium exposure increases the risk of endometrial ...
... pregnancy. Infertility. ADHD. Erectile dysfunction. Over the last several ... treated as medical problems. They,ve been "medicalized." In the ... of Social Science and Medicine , Brandeis researchers ... and a handful of other common conditions on escalating ...
... Best ... specialize in the R&D and distribution of innovative ophtalmic products to compensate for presbyopia ... High Definition reading glasses named Varionet. , ... (PRWEB) May 17, 2010 -- Best Vision International (BVI) of ...
... , This release is available in ... The world,s biggest investigation on possible links between cell ... a Canadian scientist who collaborated on the Interphone International ... of Montreal and an epidemiologist at the University of ...
... ... (ARC) program makes cutting-edge nanomaterials processing equipment more accessible and valuable , ... Newton, MA ... Microfluidizer(R) high shear fluid processors, has initiated a formal collaboration program to further ...
... ... Treatment Helps Patients Reverse Sun Damage and Restore the Health of Their Skin without ... ... extensive sun damage, resulting in wrinkles, sagging, age spots, discoloration and other unsightly symptoms. ...
Cached Medicine News:Health News:American Cancer Society awards 152 new research and training grants 2Health News:American Cancer Society awards 152 new research and training grants 3Health News:American Cancer Society awards 152 new research and training grants 4Health News:American Cancer Society awards 152 new research and training grants 5Health News:American Cancer Society awards 152 new research and training grants 6Health News:The cost of medicalizing human conditions 2Health News:Introducing a New Generation of Reading and Computer Glasses 2Health News:Introducing a New Generation of Reading and Computer Glasses 3Health News:World's biggest study on cell phones and brain cancer inconclusive 2Health News:Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives 2Health News:Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives 3Health News:Microfluidics Promotes Scientific University Research Using Nanotechnology with Innovation Incentives 4Health News:Epione Reveals a ‘Bright' New Solution for Dull, Sun Damaged Skin 2
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... Bio-Rad isotopic anemia assays ... minimal ,pipetting steps for ... about the processes ,involved ... the benefit to your ...
... The ImmunoDOT Autoimmunity Screening Panel ... test for screening and detection,of autoantibodies ... DNA, SS-A/SS-B, RNP/Sm) in serum, and ... diagnosis of systemic lupus erythematosus (SLE), ...
The MESACUP ANA Test Kit is a semi-quantitative enzyme-linked immunosorbent assay,(ELISA) for the detection of specific anti-nuclear antibodies in human serum as an aid in,the determination of autoim...
Medicine Products: